Tamsulosin Hydrochloride Capsule
Product Images NDC 55154-2142

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 55154-2142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

0.4mg Bag Label (262d5283 99e2 6377 E063 6394a90a60b5 00)

0.4mg Bag Label (262d5283 99e2 6377 E063 6394a90a60b5 00)
Tamsulosin Hydrochloride Capsules, USP 0.4mg is a medication indicated for a specific dosage, typically found in packages of 10 capsules. The product contains Tamsulosin Hydrochloride, USP 0.4 mg per capsule. It is recommended to refer to the package insert for detailed prescribing information, precautions, and warnings. The storage conditions should be maintained between 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). This medication is only available through prescription (RX ONLY). The packaging is not child-resistant and is designed for institutional use. It is essential to keep this and all medications out of children's reach and to not use the product if the blister is torn or broken. The product is distributed by American Health Packaging and is from NDC # 68382132, Zydus Pharmaceuticals USA Inc. Pharmacies should dispense this medication with patient information. There is additional distribution through Cardinal Health, based in Dublin, Ohio.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
FDA Label Image

Figure 2a (Figure 2a)

Figure 2a (Figure 2a)
This text appears to be a table showing the mean change in treatment over different time points. It includes data on the duration of treatment in weeks and the number of participants at each time point. The data seems to be related to the effects of a specific treatment or medication.*
FDA Label Image

Figure 2b (Figure 2b)

Figure 2b (Figure 2b)
This data appears to represent a study on the mean change in response to different treatments over a certain duration of weeks. The treatments mentioned are 0.4 mg, 0.8 mg, and placebo. The numbers in parentheses represent the sample sizes for each treatment group. The study includes a total of 857 participants.*
FDA Label Image

Figure 3a (Figure 3a)

Figure 3a (Figure 3a)
Mean Change in treatment of -0.08 mg, 0.04 mg, and Placebo was evaluated using a duration of treatment for weeks as presented in the data.*
FDA Label Image

Figure 3b (Figure 3b)

Figure 3b (Figure 3b)
This is a list of measurements and treatment information possibly related to medical data. The values provided seem to include changes in measurements, treatment details such as dosage levels, and the duration of treatment in weeks. The text mentions different treatment groups involving drugs or placebo and also includes codes related to the specific treatment and duration details.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.